Wayne Kotzker, MD
Nephrology · Fort Lauderdale, FLNPI 1124120019
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $362,076 of the $472,068 with a category attached, or 76.7%. It is spread thinly across 34 manufacturers, the largest accounting for just 21.3%. 2025 is the largest year on record at $138,460, 6.5 times the $21,359 reported in 2019. Among nephrology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,118 payments — averaging $422.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$101K
- AstraZeneca$94K
- Amgen$85K
- Travere Therapeutics, Inc.$49K
- Ardelyx, Inc.$40K
- Calliditas Therapeutics US Inc.$23K
- plus $81K from 28 others
Across 436 payments — averaging $6675.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.4M
- Bayer$705K
- GSK$444K
- Pfizer$318K
- Travere Therapeutics, Inc.$33K
- Akebia Therapeutics Inc$26K
- plus $22K from 1 others
What the payments were for
- Consulting fees$41,3149%
- Speaking & faculty fees$362,07677%
- Travel & lodging$39,7818%
- Food & beverage$28,7016%
- Education$1960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 128 | $100,522 |
| AstraZeneca(2 entities) | 212 | $94,030 |
| Amgen(2 entities) | 204 | $84,983 |
| Travere Therapeutics, Inc. | 112 | $48,691 |
| Ardelyx, Inc. | 65 | $39,908 |
| Calliditas Therapeutics US Inc. | 25 | $22,532 |
| Otsuka America Pharmaceutical, Inc. | 63 | $19,832 |
| GSK | 24 | $15,998 |
| Boehringer Ingelheim | 35 | $15,598 |
| Lilly USA, LLC | 16 | $13,946 |
| Fresenius USA Marketing, Inc. | 17 | $3,842 |
| Akebia Therapeutics Inc | 26 | $2,434 |
| Sobi, Inc | 2 | $2,279 |
| OPKO Pharmaceuticals, LLC | 52 | $2,235 |
| Vantive US Healthcare LLC | 12 | $1,421 |
| Mallinckrodt Hospital Products Inc. | 29 | $554 |
| Novartis | 11 | $485 |
| Novo Nordisk AS | 1 | $400 |
| Baxter Healthcare | 4 | $393 |
| Vifor Pharma, Inc. | 20 | $369 |
| Novo Nordisk | 13 | $326 |
| ANI Pharmaceuticals, Inc. | 17 | $281 |
| Johnson & Johnson | 2 | $250 |
| Aurinia Pharma U.S., Inc. | 6 | $180 |
| La Jolla Pharmaceutical Company | 3 | $147 |
| Esperion Therapeutics, Inc. | 2 | $131 |
| Mallinckrodt Enterprises LLC | 7 | $121 |
| Shire North American Group Inc | 3 | $52 |
| Medtronic | 1 | $27 |
| Avion Pharmaceuticals | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Cumberland Pharmaceuticals, Inc. | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$472,068 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 244 | $223,510 |
| KerendiaFinerenone | 121 | $124,220 |
| JardianceEmpagliflozin | 95 | $98,025 |
| LokelmaSodium Zirconium Cyclosilicate | 60 | $66,178 |
| VeltassaPatiromer Calcium Sorbitex | 22 | $46,424 |
| OzempicSemaglutide | 33 | $42,287 |
| RayaldeeCalcifediol | 21 | $39,529 |
| EliquisApixaban | 14 | $18,538 |
| RybelsusSemaglutide | 13 | $13,288 |
| Febuxostat | 32 | $6,400 |
| Mycophenolic AcidMycophenolate Sodium | 12 | $5,860 |
| Allopurinol | 176 | $4,513 |
| Sevelamer Carbonate | 41 | $4,264 |
| Potassium Citrate ErPotassium Citrate | 22 | $3,550 |
| Irbesartan | 116 | $3,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $94,030 | $289,688304 claims |
| BayerKerendia | $100,522 | $124,220121 claims |
| Boehringer IngelheimJardiance | $15,598 | $98,02595 claims |
| Novo NordiskOzempic, Rybelsus | $326 | $55,57646 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $2,235 | $39,52921 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $281 | $1,22741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 756 nephrology providers in Florida.
Other nephrology in Fort Lauderdale
- Carlos BejarFort Lauderdale$530K
- Rafael Baez BonillaFort Lauderdale$175K
- Reinaldo RosarioFort Lauderdale$75K
- Parham EftekhariFort Lauderdale$22K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Gabriel ContrerasMiami$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.